Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 4/5 core metricsLatest reported free cash flow was -$77M.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Free cash flow was negative
Latest reported free cash flow was -$77M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.
- Shareholders' equity was non-positive
Debt/equity is shown as not meaningful rather than as a negative leverage ratio.
Why this surfaced
Same-period reported shareholders' equity was zero or negative; review the balance sheet and capital structure. Period end 2025-12-31.
- 8 filing risk checks flagged
Flagged areas: Earnings quality, Solvency & liquidity, Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue expanded
Latest reported annual revenue changed +10.4% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
- Operating margin improved
Operating margin changed +98.8 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Earnings quality
- Solvency & liquidity
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Non Cash Royalty Revenue$109Mshare n/a+7.5% yoy
- Non Cash Revenue Related To Sale Of Future Royalties$109Mshare n/a+7.5% yoy
- Pre Commercial Product Revenue$4.24Mshare n/ano prior
- Other$1.04Mshare n/a-48.3% yoy
- Revenue$1.04Mshare n/a-48.3% yoy
- Research And Development Revenue$334Kshare n/a-30.7% yoy
- Clinical Product Revenue$334Kshare n/a-30.7% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$113M99.1%+11.5% yoy
- Outside the United States$1.04M0.9%-48.3% yoy
Members sum to the consolidated $114M for this period.
- Non Cash Royalty Revenue$29.1Mshare n/a+23.7% yoy
- Non Cash Royalty Revenue Related To The Sale Of Future Royalties$29.1Mshare n/a+23.7% yoy
- Pre Commercial Product Revenue$4.59Mshare n/ano prior
- Revenue$0share n/a-100.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 3,990 US-listed filers · 777 in Materials| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $114M | 29thof 3,301 bottom third | 47thof 522 middle third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 10.4% | 62ndof 3,137 middle third | 56thof 473 middle third |
Operating margin operating income ÷ revenue | -17.7% | 27thof 2,819 bottom third | 52ndof 483 middle third |
Net margin net income ÷ revenue | -2.7% | 38thof 3,263 middle third | 60thof 518 middle third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | -67.6% | 14thof 2,679 bottom third | 37thof 433 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 12.1% | 23rdof 2,895 bottom third | 43rdof 476 middle third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 6 days | 93rdof 2,398 top third | 94thof 387 top third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
Not available for AGEN yet: Earnings-quality fields arrive with this issuer's next re-crawl (sec_screen_v6)..
Point-in-time ledger
Not available for AGEN yet: The point-in-time ledger arrives with this issuer's next re-crawl (sec_screen_v6)..
Notes by disclosure type
Not available for AGEN yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.